|Systematic (IUPAC) name|
|Licence data||US FDA:|
|14px (what is this?)|
It is marketed in tablet form under the trade name Edarbi as the prodrug azilsartan medoxomil (INN, codenamed TAK-491). On 25 February 2011, the U.S. Food and Drug Administration approved azilsartan medoxomil for the treatment of high blood pressure in adults. On March 8, 2012, Health Canada approved the drug for mild to moderate essential hypertension. 
Mechanism of action
Azilsartan medoxomil lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.
- "FDA approves Edarbi to treat high blood pressure" (Press release). U.S. Food and Drug Administration. February 25, 2011. Retrieved 2011-03-01.
- Notice of Decision for EDARBI
Lua error in package.lua at line 80: module 'Module:Buffer' not found.